NIOSHTIC-2 Publications Search
Inhibition of methotrexate-induced chromosomal damage by folinic acid in V79 cells.
Keshava-C; Keshava-N; Whong-WZ; Nath-J; Ong-TM
Mutat Res 1998 Feb; 397(2):221-228
Methotrexate (MTX), an anticancer compound, is widely used in the treatment of leukemia. It induces cytogenetic damage as well as cytostatic effects on a variety of cell systems. Folinic acid (Leucovorin) is generally administered along with MTX as a rescue agent to decrease MTX-induced toxicity. However, information regarding the inhibitory effect of folinic acid against cytogenetic damage caused by MTX is limited. This study was conducted to assess the cytogenetic effect of MTX and its inhibition by folinic acid (FA) using the micronucleus and chromosomal aberration assays concurrently. Exponentially growing V79 cells were treated with MTX at five different concentrations (5-100 micrograms ml-1) with S9 microsomal fraction for 6 h and post-treated with two concentrations of FA (5 or 50 micrograms) for 40 h. Results indicate that MTX alone induced a concentration-related increase in % micronucleated binucleated cells (MNBN) and % aberrant cells (Abs). There was a decrease in nuclear division index (NDI) with increase in MTX concentration. Similarly, the mitotic index (MI) also decreased in all concentrations of MTX tested. The addition of FA at 50 micrograms ml-1 significantly reduced % MNBN (40-68%) and % Abs (36-77%). Inhibition was also seen at 5 micrograms FA (12 to 54% for MNBN and 20 to 61% for Abs). These results indicate that FA is capable of reducing the cytogenetic damage induced by MTX and appears to be an anticlastogenic agent.
Cancer; Toxins; Toxic-effects; Cellular-structures; Cellular-reactions; Cellular-function; Cellular-uptake; Cell-transformation; In-vivo-studies; In-vitro-studies; Chromosome-damage; Chromosome-disorders
Issue of Publication
Page last reviewed: April 12, 2019
Content source: National Institute for Occupational Safety and Health Education and Information Division